Schond Greenway Halozyme Therapeutics 858-704-8352 ir@halozyme.com Jim Mazzola Halozyme Therapeutics 858-704-8122 ir@halozyme.com HALOZYME REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS - Revenues increase 56 per

Halozyme Therapeutics

Halozyme Therapeutics

HALOZYME REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS

- Revenues increase 56 percent to $18.7 million, loss narrows to $15.1 million -

- Royalty revenue increases 70 percent from the fourth quarter-

- Interim results of Halozyme's randomized Phase 2 study in pancreatic cancer to be

presented at the annual meeting of the American Society of Clinical Oncology -

SAN DIEGO, May 11, 2015 -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results for the first quarter ended March 31, 2015. Financial highlights include revenues of $18.7 million and a net loss of $15.1 million, or $0.12 per share compared to revenues of $12.0 million and a net loss of $26.5 million, or $0.22 per share, for the first quarter of 2014.

"We continued to execute well in the first quarter against a focused strategy in oncology, ramping investments in our core program and achieving significant milestones toward the initiation of a Phase 3 study in pancreatic cancer patients early next year," said Dr. Helen Torley, president and chief executive officer. "In addition to this strategic progress, we exited the quarter in a much stronger financial position than last year due to a steady increase in royalty revenues from our rHuPH20 platform."

First Quarter 2015 Highlights and Subsequent Events

The company plans to use a companion diagnostic test to prospectively identify and select patients with high levels of HA for its Phase 3 trial. The FDA provided feedback supporting the selection of high-HA patients and confirmed that an Investigational Device Exemption - or IDE - will be required prior to initiating the Phase 3 study. An IDE is a

regulatory application that summarizes the methodology, validation and proposed cut-point for patient selection. The company plans to submit the IDE to support the late Q1 2016 Study 301 start.

In April, the company also announced plans to present the interim results of the study during an oral presentation by Dr. Sunil Hingorani, a principal investigator, at the annual meeting of the American Society of Clinical Oncology (ASCO).

First Quarter 2015 Financial Highlights

Financial Outlook for 2015

For the full year 2015, the company reiterated its previously disclosed guidance of:

Webcast and Conference Call

Halozyme will webcast its quarterly update conference call today, May 11, 2015 at 4:30 p.m. ET/1:30 p.m. PT. During the call, management will discuss financial results and provide a business update. To listen to the live webcast please visit the "Investors" section of Halozyme's corporate website and view additional documents related to the call at www.halozyme.com. A webcast replay will be available shortly after the call at the same address. To participate by phone, please dial (866) 710-0179 (domestic callers) or (334) 323-7224 (international callers) using passcode 769890. A telephone replay will be available shortly after the call by dialing (877) 919-4059 (domestic callers) or (334) 323-0140 (international callers) using replay passcode 48722220.

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, our investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer and non-small cell lung cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE , which enables biologics and small molecule compounds that are currently administered intravenously to be delivered subcutaneously. Halozyme is headquartered in San Diego. For more information visit halozyme.com.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the Company's future expectations and plans for growth in 2015, the development and commercialization of product candidates and the potential benefits and attributes of such product candidates and expected financial outlook for 2015) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures and costs, unexpected fluctuations or changes in revenues from collaborators, unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 11, 2015.

Halozyme Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except per share data)

Halozyme Therapeutics, Inc.

Condensed Consolidated Balance Sheets